Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Arvinas, Inc. (ARVN : NSDQ)

• Company Description    Arvinas Inc. is a biopharmaceutical company for patients suffering from debilitating and life-threatening diseases. It engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Arvinas Inc. is based in CT, United States. Number of Employees: 280

• Price / Volume Information    Yesterday's Closing Price: $44.07 Daily Weekly Monthly 20 Day Moving Average: 642,833 shares Shares Outstanding: 53.17 (millions) Market Capitalization: $2,343.02 (millions) Beta: 2.05 52 Week High: $108.47 52 Week Low: $37.41 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -31.28% -22.60% 12 Week -33.56% -26.95% Year To Date -46.35% -34.44%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 5 SCIENCE PARK 395 WINCHESTER AVE - NEW HAVEN,CT 06511 USA ph: 203-535-1456 fax: - ir@arvinas.com http://www.arvinas.com

• General Corporate Information    Officers John Houston - President; Chief Executive Officer and Director Timothy Shannon - Chairman Sean Cassidy - Chief Financial Officer Linda Bain - Director Wendy Dixon - Director Peer Information Arvinas, Inc. (CORR.) Arvinas, Inc. (RSPI) Arvinas, Inc. (CGXP) Arvinas, Inc. (BGEN) Arvinas, Inc. (GTBP) Arvinas, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 04335A105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/04/22 Share - Related Items Shares Outstanding: 53.17 Most Recent Split Date: (:1) Beta: 2.05 Market Capitalization: $2,343.02 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.02 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.52 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 11.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.24 Price/Cash Flow: - Price / Sales: 35.87 EPS Growth vs. Year Ago Period: -42.86% vs. Previous Quarter: -20.00% Sales Growth vs. Year Ago Period: 336.90% vs. Previous Quarter: -7.98% ROE 03/31/22 - -29.38 12/31/21 - -27.31 09/30/21 - -27.02 ROA 03/31/22 - -16.05 12/31/21 - -16.93 09/30/21 - -19.69 Current Ratio 03/31/22 - 6.12 12/31/21 - 5.93 09/30/21 - 8.64 Quick Ratio 03/31/22 - 6.12 12/31/21 - 5.93 09/30/21 - 8.64 Operating Margin 03/31/22 - -326.72 12/31/21 - -409.29 09/30/21 - -794.97 Net Margin 03/31/22 - -326.72 12/31/21 - -409.29 09/30/21 - -794.97 Pre-Tax Margin 03/31/22 - -319.77 12/31/21 - -408.99 09/30/21 - -794.98 Book Value 03/31/22 - 13.60 12/31/21 - 14.78 09/30/21 - 16.62 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.14 12/31/21 - 0.13 09/30/21 - 0.12

Powered by Zacks Investment Research ©